```html

Zollinger‑Ellison Disease (Gastrin‑Producing Tumor)

Overview

Zollinger‑Ellison disease (ZED) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (called gastrinomas) develop in the pancreas, duodenum, or nearby tissue. The excess gastrin hormone stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption.

Who it affects

• Adults aged 30‑60 are most commonly diagnosed, although children and older adults can be affected.
• Both sexes are equally affected, but some series show a slight male predominance (≈55 %).
• Approximately 20‑25 % of patients have an inherited form called multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence

• Incidence is about 0.5–2 cases per million people per year worldwide.
• Overall prevalence is estimated at 3–5 cases per million (≈10,000–15,000 individuals in the United States).

Despite its rarity, ZED is clinically important because it is the most common cause of severe, refractory peptic ulcer disease and can metastasize in up to 60 % of cases if untreated.

Symptoms

Symptoms arise from two main mechanisms: (1) hyper‑acid production and (2) tumor mass effect or metastasis. Below is a comprehensive list.

Gastro‑intestinal symptoms

• Recurrent abdominal pain: Often described as burning or gnawing, worsens 1–2 hours after meals.
• Peptic ulcers: Multiple ulcers may develop in the duodenum, jejunum, or esophagus; classic ulcers are larger (>2 cm) and may be refractory to standard therapy.
• Diarrhea: Occurs in 30‑50 % of patients; can be watery, fatty (steatorrhea) or mixed, due to acid inactivation of pancreatic enzymes.
• Nausea & vomiting: Especially after large meals.
• Gastro‑intestinal bleeding: Presents as melena or hematemesis when ulcers erode into vessels.

Systemic symptoms

• Weight loss: Result of malabsorption and chronic diarrhea.
• Fatigue & anemia: From chronic blood loss or iron deficiency.
• Heartburn or reflux: Due to excessive acid.
• Glossitis, mouth sores: Acid damage to the oral mucosa.

Symptoms related to tumor location or metastasis

• Pancreatic mass: May cause a palpable abdominal lump or vague back pain.
• Liver metastasis: Right‑upper‑quadrant discomfort, jaundice, or hepatic enlargement.
• Bone metastasis (rare): Bone pain or pathological fractures.

Causes and Risk Factors

Primary cause

ZED is caused by a gastrinoma, a neuroendocrine tumor that secretes gastrin autonomously. Over 90 % of gastrinomas arise in the “gastrinoma triangle” – the area bounded by the junction of the cystic and common bile ducts, the second/third portions of the duodenum, and the head of the pancreas.

Genetic factors

• MEN‑1 syndrome: Mutations in the MEN1 tumor suppressor gene predispose to pancreatic neuroendocrine tumors, including gastrinomas. Up to 25 % of ZED cases are MEN‑1 related.
• Familial isolated gastrinoma: Rare autosomal‑dominant inheritance without other MEN‑1 features.

Risk factors

• Family history of MEN‑1 or gastrinoma.
• Known genetic mutation in MEN1 or CDC73 (very rare).
• Prior history of pancreatic neuroendocrine tumors.

Most patients have no identifiable risk factor; the tumors arise sporadically.

Diagnosis

Diagnosing ZED requires confirming hypergastrinemia, ruling out other causes of high gastrin, and locating the tumor.

Laboratory tests

• Fasting serum gastrin level: Levels > 1000 pg/mL (≈10× upper limit) are highly suggestive. Mild elevations can be seen with atrophic gastritis or PPI use.
• Secretin stimulation test: After intravenous secretin, gastrin rises paradoxically in ZED (≥ 120 pg/mL increase).
• Chromogranin A (CgA): Elevated in many neuroendocrine tumors; useful for monitoring.
• Acid output measurement (basal acid output, BAO): Typically >15 mEq/h in ZED.

Imaging studies

• Multiphasic CT scan (contrast‑enhanced): First‑line for tumor localisation; detects >1 cm lesions in >80 % of cases.
• MRI with diffusion‑weighted imaging: Better soft‑tissue contrast; useful for liver metastases.
• Endoscopic ultrasound (EUS): High resolution for small (<1 cm) pancreatic or duodenal lesions; allows fine‑needle aspiration for pathology.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Detects gastrinomas expressing somatostatin receptors; most sensitive for metastatic disease.
• Selective arterial secretin stimulation test (SASST): Invasive but can pinpoint lesion when non‑invasive imaging is negative.

Pathology

If tissue is obtained (via EUS‑FNA or surgery), pathology shows well‑differentiated neuroendocrine cells positive for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Treatment aims to control acid hypersecretion, eradicate or reduce tumor burden, and monitor for recurrence.

Medical management – acid control

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often 2–4 times the standard ulcer dose (e.g., omeprazole 40–80 mg daily).
• H2‑receptor antagonists: Cimetidine or ranitidine can be added if PPIs are insufficient, though PPIs are more effective.
• Histamine‑2‑receptor tachyphylaxis: May develop; monitor acid control with symptom diary and, if needed, repeat gastric pH testing.

Surgical treatment

• Curative resection: Enucleation or pancreatoduodenectomy (Whipple) for localized gastrinomas < 2 cm without metastasis.
• Debulking surgery: For unresectable or metastatic disease; removal of ≥ 90 % of tumor mass can improve symptom control.
• Liver-directed therapies: Radiofrequency ablation, hepatic artery embolization, or peptide‑receptor radionuclide therapy (PRRT) for liver metastases.

Systemic therapies

• Somatostatin analogues (SSAs): Octreotide or lanreotide bind somatostatin receptors, reducing gastrin secretion and tumor growth. Typical dose: octreotide LAR 30 mg IM every 4 weeks.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic neuroendocrine tumors; may slow progression.
• Peptide‑receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiotherapy to somatostatin‑receptor‑positive tumors; improves progression‑free survival (NETTER‑1 trial).
• Chemotherapy: Reserved for high‑grade or rapidly progressive disease; regimens such as streptozocin‑5‑FU or temozolomide‑capecitabine are used.

Lifestyle and supportive measures

• Low‑fat, low‑spice diet while ulcer disease heals.
• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) and smoking, which worsen ulcer risk.
• Calcium and vitamin D supplementation if malabsorption leads to deficiencies.

Living with Zollinger‑Ellison Disease (gastrin‑producing tumor)

Medication adherence

• Take PPIs exactly as prescribed; missing doses can trigger severe rebound acid hypersecretion.
• Carry a rescue antacid (e.g., calcium carbonate) for breakthrough symptoms.

Monitoring

• Serum gastrin and chromogranin A every 3–6 months during active treatment.
• Annual imaging (MRI or CT) to detect new lesions or metastasis.
• Endoscopic surveillance every 1–2 years if ulcers persist or recur.

Dietary tips

• Eat smaller, frequent meals to reduce gastric load.
• Limit caffeine, alcohol, and very acidic foods (citrus, tomatoes) which can aggravate symptoms.
• Include protein‑rich foods to counteract protein loss from diarrhea.

Managing diarrhea

• Use pancreatic enzyme supplements (e.g., pancrelipase) if fat malabsorption is significant.
• Consider loperamide or diphenoxylate‑atropine for persistent watery stools, under physician guidance.

Psychosocial support

• Join patient advocacy groups (e.g., NET Patient Foundation) for peer support.
• Consider counseling or mental‑health services—chronic disease can affect mood and quality of life.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for individuals with a family history of MEN‑1.
• Avoid long‑term, high‑dose proton‑pump inhibitor use without a clear indication—some data suggest chronic hypergastrinemia may theoretically promote neuroendocrine proliferation, though evidence is inconclusive.
• Maintain a healthy lifestyle (no smoking, moderate alcohol) to lower overall cancer risk.

Complications

If untreated or inadequately managed, ZED may lead to serious complications:

• Refractory or perforated peptic ulcer disease: Can cause peritonitis, emergency surgery, and mortality.
• Severe gastrointestinal bleeding: May require endoscopic hemostasis, transfusion, or surgery.
• Malnutrition & electrolyte disturbances: Chronic diarrhea leads to calcium, magnesium, and potassium loss.
• Metastatic disease: Liver is the most common site; hepatic involvement can cause jaundice, ascites, and hepatic failure.
• Gastro‑esophageal reflux disease (GERD) complications: Esophagitis, Barrett’s esophagus, or adenocarcinoma.
• Secondary infections: Over‑use of acid suppression may increase risk of Clostridioides difficile infection.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe abdominal pain that does not improve with medication.
• Vomiting blood (bright red) or coffee‑ground material.
• Black, tarry stools (melena) indicating possible upper‑GI bleeding.
• Sudden onset of high fever, chills, or severe abdominal distention – possible perforation or infection.
• Rapid heart rate (>110 bpm) with dizziness or fainting, especially with ongoing bleeding.
• Severe, unremitting diarrhea causing dehydration (dry mouth, little urine, dizziness).

Even if symptoms are mild but new or worsening, contact your gastroenterologist promptly to adjust therapy.

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – National Institute of Diabetes and Digestive and Kidney Diseases, American College of Gastroenterology Guidelines (2022), NCCN Guidelines for Neuroendocrine Tumors, WHO Classification of Tumours of the Digestive System (2022), Cleveland Clinic, NEJM 2021; Gastroenterology 2020; JAMA Oncology 2023.

```